Lung Disease News |
Severe Asthma Reduced in Phase 3 Benralizumab Tests
Lung Disease News AstraZeneca recently announced that the new severe asthma medicine benralizumab met the primary endpoints in two Phase 3 registration trials. Findings of the trials called SIROCCO and CALIMA, revealed that the monoclonal antibody compound was well … |
View full post on asthma – Google News